Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant icotinib or ensartinib vs observation in stage IA EGFR/ALK-positive NSCLC after surgery
ChiCTR2500112620Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Adjuvant icotinib or ensartinib with Observation (2 arms). Primary endpoint: 2-year disease-free survival rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
icotinibensartinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500112620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112620.